Viridian hits 52-week high on data for thyroid eye disease candidate

Aug. 15, 2022 1:52 PM ETViridian Therapeutics, Inc. (VRDN)By: Dulan Lokuwithana, SA News Editor

Wall street sign in New York with New York Stock Exchange background

naphtalina/iStock via Getty Images

  • The shares of Viridian Therapeutics (NASDAQ:VRDN) jumped ~60% on above-average volume to reach the highest level since Jan. 2021 after the clinical-stage biotech announced data for its thyroid eye disease candidate VRDN-001 from a Phase 1/2 trial.
  • The company said that initial data from the eight-patient 10mg/kg cohort indicated that two infusions of VRDN-001 led to significant and rapid improvement of both signs and symptoms of TED at Week 6.
  • In reaction to data, Evercore ISI raised the price target for Viridian (VRDN) to a new Street high of $50 per share. Forecasting ~$1.4B peak U.S. sale opportunity for the company’s assets in TED, the firm argues that despite its near 60% gain on Monday, the stock remains undervalued.
  • Viridian (VRDN) expects to disclose two more data readouts for 3mg/kg and 20mg/kg cohorts from the ongoing TED trial in 4Q 2022.
  • Wall Street stands firmly behind the prospects of Viridian (VRDN) with nine Buy ratings and no Hold or Sell ratings.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.